Denosumab and bisphosphonates: Different mechanisms of action and effects

Schaffler, 2003, Role of bone turnover in microdamage, Osteoporos Int, 14, S73, 10.1007/s00198-003-1477-1

Martin, 2009, Molecular mechanisms in coupling of bone formation to resorption, Crit Rev Eukaryot Gene Expr, 19, 73, 10.1615/CritRevEukarGeneExpr.v19.i1.40

Bruzzaniti, 2006, Molecular regulation of osteoclast activity, Rev Endocr Metab Disord, 7, 123, 10.1007/s11154-006-9009-x

Russell, 2001, Clinical disorders of bone resorption, Novartis Found Symp, 232, 251, 10.1002/0470846658.ch17

Khosla, 2005, Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women, J Clin Endocrinol Metab, 90, 5096, 10.1210/jc.2005-0396

Seeman, 2003, Invited review: pathogenesis of osteoporosis, J Appl Physiol, 95, 2142, 10.1152/japplphysiol.00564.2003

Zebaze, 2010, Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study, Lancet, 375, 1729, 10.1016/S0140-6736(10)60320-0

Eghbali-Fatourechi, 2003, Role of RANK ligand in mediating increased bone resorption in early postmenopausal women, J Clin Invest, 111, 1221, 10.1172/JCI200317215

Theill, 2002, RANK-L and RANK: T cells, bone loss, and mammalian evolution, Annu Rev Immunol, 20, 795, 10.1146/annurev.immunol.20.100301.064753

Guerrini, 2008, Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations, Am J Hum Genet, 83, 64, 10.1016/j.ajhg.2008.06.015

Sobacchi, 2007, Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL, Nat Genet, 39, 960, 10.1038/ng2076

Cundy, 2005, Recombinant osteoprotegerin for juvenile Paget's disease, N Engl J Med, 353, 918, 10.1056/NEJMoa050893

Bekker, 2001, The effect of a single dose of osteoprotegerin in postmenopausal women, J Bone Miner Res, 16, 348, 10.1359/jbmr.2001.16.2.348

Yoshida, 1990, The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene, Nature, 345, 442, 10.1038/345442a0

Elford, 1987, Murine osteoblastlike cells and the osteogenic cell MC3T3-E1 release a macrophage colony-stimulating activity in culture, Calcif Tissue Int, 41, 151, 10.1007/BF02563795

Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X

Boyle, 2003, Osteoclast differentiation and activation, Nature, 423, 337, 10.1038/nature01658

Asagiri, 2007, The molecular understanding of osteoclast differentiation, Bone, 40, 251, 10.1016/j.bone.2006.09.023

Mori, 2008, Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development, J Immunol, 181, 4742, 10.4049/jimmunol.181.7.4742

Takayanagi, 2009, Osteoimmunology and the effects of the immune system on bone, Nat Rev Rheumatol, 5, 667, 10.1038/nrrheum.2009.217

Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852

Theoleyre, 2004, The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine Growth Factor Rev, 15, 457, 10.1016/j.cytogfr.2004.06.004

Wright, 2009, RANK, RANKL and osteoprotegerin in bone biology and disease, Curr Rev Musculoskelet Med, 2, 56, 10.1007/s12178-009-9046-7

Kearns, 2008, Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease, Endocr Rev, 29, 155, 10.1210/er.2007-0014

Fuller, 1993, Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts, J Exp Med, 178, 1733, 10.1084/jem.178.5.1733

Burgess, 1999, The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts, J Cell Biol, 145, 527, 10.1083/jcb.145.3.527

Lacey, 2000, Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo, Am J Pathol, 157, 435, 10.1016/S0002-9440(10)64556-7

Niida, 1999, Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption, J Exp Med, 190, 293, 10.1084/jem.190.2.293

Niida, 2005, VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice, Proc Natl Acad Sci USA, 102, 14016, 10.1073/pnas.0503544102

Stewart, 1982, Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity, J Clin Endocrinol Metab, 55, 219, 10.1210/jcem-55-2-219

Martin, 2005, Osteoclast-derived activity in the coupling of bone formation to resorption, Trends Mol Med, 11, 76, 10.1016/j.molmed.2004.12.004

Pierroz, 2010, Are osteoclasts needed for the bone anabolic response to PTH? A study of intermittent PTH with denosumab or alendronate in knock-in mice expressing humanized RANKL, J Biol Chem, 285, 28164, 10.1074/jbc.M110.101964

Pederson, 2008, Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate, Proc Natl Acad Sci USA, 105, 20764, 10.1073/pnas.0805133106

Zhao, 2006, Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis, Cell Metab, 4, 111, 10.1016/j.cmet.2006.05.012

Sims, 2010, EPHs and ephrins: many pathways to regulate osteoblasts and osteoclasts, IBMS BoneKEy, 7, 304, 10.1138/20100463

Henriksen, 2009, Local communication on and within bone controls bone remodeling, Bone, 44, 1026, 10.1016/j.bone.2009.03.671

Recker, 2009, Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis, J Bone Miner Res, 24, 1358, 10.1359/jbmr.090315

Reid, 2010, Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies, J Bone Miner Res, 25, 2256, 10.1002/jbmr.149

Russell, 2008, Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy, Osteoporos Int, 19, 733, 10.1007/s00198-007-0540-8

Hughes, 1989, Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow, J Clin Invest, 83, 1930, 10.1172/JCI114100

Boonekamp, 1986, Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix, Bone Miner, 1, 27

Mabilleau, 2010, Bisphosphonates affect human osteoclast development in vitro, Bone, 46, S63, 10.1016/j.bone.2010.01.152

Francis, 1969, Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo, Science, 165, 1264, 10.1126/science.165.3899.1264

Benedict, 1982, The physical chemistry of the disphosphonates — its relationship to their medical activity, 1

Ebrahimpour, 1995, Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies, 125

Fleisch, 2000

Henneman, 2008, Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro, J Biomed Mater Res A, 85, 993, 10.1002/jbm.a.31599

Nancollas, 2006, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite, Bone, 38, 617, 10.1016/j.bone.2005.05.003

Ebetino, 1998, Mechanisms of action of etidronate and other bisphosphonates, Rev Contemp Pharmacother, 9, 233

Sato, 1991, Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure, J Clin Invest, 88, 2095, 10.1172/JCI115539

Thompson, 2006, Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis, Mol Pharmacol, 69, 1624, 10.1124/mol.105.020776

Coxon, 2008, Vesicular trafficking in osteoclasts, Semin Cell Dev Biol, 19, 424, 10.1016/j.semcdb.2008.08.004

van Beek, 1996, Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group, J Bone Miner Res, 11, 1492, 10.1002/jbmr.5650111016

Frith, 2001, The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis, Arthritis Rheum, 44, 2201, 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E

Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3

Ominsky, 2007, The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys, Osteoporos Int, 18, 1073, 10.1007/s00198-007-0363-7

Body, 2003, A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases, Cancer, 97, 887, 10.1002/cncr.11138

Schwarz, 2007, Clinical development of anti-RANKL therapy, Arthritis Res Ther, 9, S7, 10.1186/ar2171

Sordillo, 2003, RANK-Fc: a therapeutic antagonist for RANK-L in myeloma, Cancer, 97, 802, 10.1002/cncr.11134

McClung, 2006, Denosumab in postmenopausal women with low bone mineral density, N Engl J Med, 354, 821, 10.1056/NEJMoa044459

Tabrizi, 2006, Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov Today, 11, 81, 10.1016/S1359-6446(05)03638-X

Kostenuik, 2009, Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL, J Bone Miner Res, 24, 182, 10.1359/jbmr.081112

Emery, 1998, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J Biol Chem, 273, 14363, 10.1074/jbc.273.23.14363

Amgen Europe

Weinstein, 2009, Giant osteoclast formation and long-term oral bisphosphonate therapy, N Engl J Med, 360, 53, 10.1056/NEJMoa0802633

Stolina, 2007, OPG prevents osteopenia in arthritic rats via different mechanisms than bisphosphonate therapy, J Bone Miner Res, 22, S475

Tat, 2006, OPG/membranous–RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation, Bone, 39, 706, 10.1016/j.bone.2006.03.016

Lambert, 2007, Further insights in the mechanisms of interleukin-1β stimulation of osteoprotegerin in osteoblast-like cells, J Bone Miner Res, 22, 1350, 10.1359/jbmr.070508

Samadfam, 2007, Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice, J Bone Miner Res, 22, 55, 10.1359/jbmr.060915

Rogers, 2003, New insights into the molecular mechanisms of action of bisphosphonates, Curr Pharm Des, 9, 2643, 10.2174/1381612033453640

Gasser, 2008, Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat, J Bone Miner Res, 23, 544, 10.1359/jbmr.071207

Teti, 2009, Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited, Bone, 44, 11, 10.1016/j.bone.2008.09.017

Bonewald, 2008, Osteocytes, mechanosensing and Wnt signaling, Bone, 42, 606, 10.1016/j.bone.2007.12.224

Kamiya, 2008, BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway, Development, 135, 3801, 10.1242/dev.025825

Kramer, 2010, Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis, Mol Cell Biol, 30, 3071, 10.1128/MCB.01428-09

Ominsky, 2009, One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength, J Bone Miner Res, 24, 1234, 10.1359/jbmr.090215

Li, 2009, Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin, Bone, 45, 669, 10.1016/j.bone.2009.06.011

Aguirre, 2006, Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss, J Bone Miner Res, 21, 605, 10.1359/jbmr.060107

Bonewald, 2007, Osteocytes as dynamic multifunctional cells, Ann NY Acad Sci, 1116, 281, 10.1196/annals.1402.018

Plotkin, 1999, Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, J Clin Invest, 104, 1363, 10.1172/JCI6800

Plotkin, 2006, Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs, Bone, 39, 443, 10.1016/j.bone.2006.02.060

Plotkin, 2008, Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo, J Bone Miner Res, 23, 1712, 10.1359/jbmr.080617

Plotkin, 2007, A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis in vivo, J Bone Miner Res, 22, S4

Kogianni, 2004, Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis, Life Sci, 75, 2879, 10.1016/j.lfs.2004.04.048

Follet, 2007, Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading, Bone, 40, 1172, 10.1016/j.bone.2006.12.052

Roelofs, 2010, Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages, Curr Pharm Des, 16, 2950, 10.2174/138161210793563635

Fuchs, 2007, Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats, Bone, 41, 290, 10.1016/j.bone.2007.04.179

Lespessailles, 2009, Does exercise modify the effects of zoledronic acid on bone mass, microarchitecture, biomechanics, and turnover in ovariectomized rats?, Calcif Tissue Int, 85, 146, 10.1007/s00223-009-9269-z

Stadelmann, 2011, Combined effects of zoledronate and mechanical stimulation on bone adaptation in axially loaded mouse tibia, Clin Biomech, 26, 101, 10.1016/j.clinbiomech.2010.08.014

Dougall, 1999, RANK is essential for osteoclast and lymph node development, Genes Dev, 13, 2412, 10.1101/gad.13.18.2412

Bachmann, 1999, TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation, J Exp Med, 189, 1025, 10.1084/jem.189.7.1025

Ashcroft, 2003, Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin, Immunity, 19, 849, 10.1016/S1074-7613(03)00326-1

Byrne, 2005, CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin, Gut, 54, 78, 10.1136/gut.2003.035113

Kong, 1999, Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand, Nature, 402, 304, 10.1038/46303

Romas, 2002, Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis, Am J Pathol, 161, 1419, 10.1016/S0002-9440(10)64417-3

Schett, 2005, Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models, Arthritis Rheum, 52, 1604, 10.1002/art.21021

Redlich, 2002, Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin, Arthritis Rheum, 46, 785, 10.1002/art.10097

Stolina, 2009, RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies, Arthritis Res Ther, 11, R187, 10.1186/ar2879

Verdrengh, 2010, RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis, Bone, 46, 752, 10.1016/j.bone.2009.10.028

Ferrari-Lacraz, 2010, Do RANKL inhibitors (denosumab) affect inflammation and immunity?, Osteoporos Int, 22, 435, 10.1007/s00198-010-1326-y

Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med, 356, 1809, 10.1056/NEJMoa067312

Bock, 2007, Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention, J Musculoskelet Neuronal Interact, 7, 144

Delmas, 2006, Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study, Arthritis Rheum, 54, 1838, 10.1002/art.21918

Strampel, 2007, Safety considerations with bisphosphonates for the treatment of osteoporosis, Drug Saf, 30, 755, 10.2165/00002018-200730090-00003

Thompson, 2004, Statins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitro, J Bone Miner Res, 19, 278, 10.1359/JBMR.0301230

Raikkonen, 2009, Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro, Br J Pharmacol, 157, 427, 10.1111/j.1476-5381.2009.00160.x

Benzaid, 2010, Nitrogen-containing bisphosphonates and human γδ T cells, IBMS BoneKEy, 7, 208, 10.1138/20100450

Srivastava, 2009, Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion, J Bone Miner Res, 24, 334, 10.1359/jbmr.081016

Hak, 2000, Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study, Arterioscler Thromb Vasc Biol, 20, 1926, 10.1161/01.ATV.20.8.1926

Szulc, 2008, Calcifications in the abdominal aorta predict fractures in men: MINOS study, J Bone Miner Res, 23, 95, 10.1359/jbmr.070903

Bucay, 1998, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, 12, 1260, 10.1101/gad.12.9.1260

Bennett, 2006, Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice, Arterioscler Thromb Vasc Biol, 26, 2117, 10.1161/01.ATV.0000236428.91125.e6

Helas, 2009, Inhibition of receptor activator of NF-κB ligand by denosumab attenuates vascular calcium deposition in mice, Am J Pathol, 175, 473, 10.2353/ajpath.2009.080957

Fleisch, 1970, The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo, Eur J Clin Invest, 1, 12, 10.1111/j.1365-2362.1970.tb00591.x

Price, 2001, Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption, Arterioscler Thromb Vasc Biol, 21, 817, 10.1161/01.ATV.21.5.817

Price, 2002, The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption, Calcif Tissue Int, 71, 356, 10.1007/s00223-002-1006-9

Monney, 2004, Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure, Nephrol Dial Transplant, 19, 2130, 10.1093/ndt/gfh305

Schliep, 2008, Successful treatment of calciphylaxis with pamidronate, Eur J Dermatol, 18, 554

Santini, 2006, Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?, Recent Pat Anticancer Drug Discov, 1, 383, 10.2174/157489206778776989

Stresing, 2007, Bisphosphonates in cancer therapy, Cancer Lett, 257, 16, 10.1016/j.canlet.2007.07.007

Bekker, 2004, A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, J Bone Miner Res, 19, 1059, 10.1359/JBMR.040305

Rodan, 2004, Bone safety of long-term bisphosphonate treatment, Curr Med Res Opin, 20, 1291, 10.1185/030079904125004475

Reitsma, 1980, Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats, Calcif Tissue Int, 32, 145, 10.1007/BF02408534

Bone, 2004, Ten years' experience with alendronate for osteoporosis in postmenopausal women, N Engl J Med, 350, 1189, 10.1056/NEJMoa030897

Tonino, 2000, Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group, J Clin Endocrinol Metab, 85, 3109

Delmas, 2004, Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study, Osteoporos Int, 15, 792, 10.1007/s00198-004-1602-9

Sorensen, 2003, Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience, Bone, 32, 120, 10.1016/S8756-3282(02)00946-8

Ste-Marie, 2004, Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis, Calcif Tissue Int, 75, 469, 10.1007/s00223-004-0039-7

Lin, 1996, Bisphosphonates: a review of their pharmacokinetic properties, Bone, 18, 75, 10.1016/8756-3282(95)00445-9

Khan, 1997, Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis, J Bone Miner Res, 12, 1700, 10.1359/jbmr.1997.12.10.1700

Cremers, 2002, A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis, Eur J Clin Pharmacol, 57, 883, 10.1007/s00228-001-0411-8

Capparelli, 2003, Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats, J Bone Miner Res, 18, 852, 10.1359/jbmr.2003.18.5.852

Ominsky, 2008, RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats, J Bone Miner Res, 23, 672, 10.1359/jbmr.080109

Calvi, 2001, Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone, J Clin Invest, 107, 277, 10.1172/JCI11296

Ohishi, 2009, Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor, Am J Pathol, 174, 2160, 10.2353/ajpath.2009.081026

Jämsä, 2002, Mechanical properties in long bones of rat osteopetrotic mutations, J Biomech, 35, 161, 10.1016/S0021-9290(01)00203-2

Allen, 2007, Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment, J Bone Miner Res, 22, 1759, 10.1359/jbmr.070720

Komatsubara, 2003, Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra, J Bone Miner Res, 18, 512, 10.1359/jbmr.2003.18.3.512

Komatsubara, 2004, Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib, J Bone Miner Res, 19, 999, 10.1359/JBMR.040126

Mashiba, 2000, Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib, J Bone Miner Res, 15, 613, 10.1359/jbmr.2000.15.4.613

Allen, 2008, Skeletal microdamage: less about biomechanics and more about remodeling, Clin Rev Bone Miner Metab, 6, 24, 10.1007/s12018-008-9015-5

Burr, 2008, Low bone turnover and microdamage? How and where to assess it?, J Bone Miner Res, 23, 1150, 10.1359/jbmr.080307

Chapurlat, 2009, Bone microdamage: a clinical perspective, Osteoporos Int, 20, 1299, 10.1007/s00198-009-0899-9

Dobnig, 2009, Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate, J Bone Miner Res, 24, 1998, 10.1359/jbmr.090527

Johnston, 2007, The effects of combination of alendronate and human parathyroid hormone(1–34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice, Endocrinology, 148, 4466, 10.1210/en.2007-0229

Pettway, 2008, Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation, Bone, 42, 806, 10.1016/j.bone.2007.11.017

Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975

Hofbauer, 2009, Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL, Arthritis Rheum, 60, 1427, 10.1002/art.24445

Gerstenfeld, 2009, Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing, J Bone Miner Res, 24, 196, 10.1359/jbmr.081113

Ominsky, 2007, Denosumab (AMG 162), a fully human RANKL antibody, improves cortical and cancellous bone mass and bone strength in ovariectomized cynomolgus monkeys, J Bone Miner Res, 22

Ominsky, 2009, Decreased fluorochrome labeling in bone biopsies from denosumab-treated cynomolgus monkeys is related to reductions in cortical porosity and trabecular eroded surfaces, J Bone Miner Res, 24

Ominsky, 2008, Transition from alendronate to denosumab resulted in further reductions in local and systemic bone turnover parameters and reduced cortical porosity in ovariectomized cynomolgus monkeys, J Bone Miner Res, 23, S61

Chesnut, 2004, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res, 19, 1241, 10.1359/JBMR.040325

Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporos Int, 11, 83, 10.1007/s001980050010

Fogelman, 2000, Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group, J Clin Endocrinol Metab, 85, 1895

Watts, 1990, Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, N Engl J Med, 323, 73, 10.1056/NEJM199007123230201

Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2

Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial, JAMA, 280, 2077, 10.1001/jama.280.24.2077

Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201

Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493

Brown, 2009, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial, J Bone Miner Res, 24, 153, 10.1359/jbmr.0809010

Kendler, 2010, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy, J Bone Miner Res, 25, 72, 10.1359/jbmr.090716

Miller, 2008, Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial, Bone, 43, 222, 10.1016/j.bone.2008.04.007

Seeman, 2010, Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate, J Bone Miner Res, 25, 1886, 10.1002/jbmr.81

Genant, 2010, Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density, Bone, 47, 131, 10.1016/j.bone.2010.04.594

Ferrari, 2010, Bisphosphonates and denosumab: do they thicken bone cortices, and can these changes be assessed by high-resolution pQCT?, IBMS BoneKEy, 7, 182, 10.1138/20100444

Borah, 2010, Risedronate reduces intracortical porosity in women with osteoporosis, J Bone Miner Res, 25, 41, 10.1359/jbmr.090711

Pazianas, 2010, Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis, Ther Clin Risk Manag, 6, 325

Marx, 2003, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, J Oral Maxillofac Surg, 61, 1115, 10.1016/S0278-2391(03)00720-1

Almazrooa, 2009, Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review, J Am Dent Assoc, 140, 864, 10.14219/jada.archive.2009.0280

Taylor, 2010, Osteonecrosis of the jaws induced by anti-RANK ligand therapy, Br J Oral Maxillofac Surg, 48, 221, 10.1016/j.bjoms.2009.08.030

Aghaloo, 2010, Osteonecrosis of the jaw in a patient on denosumab, J Oral Maxillofac Surg, 68, 959, 10.1016/j.joms.2009.10.010

Kanis, 2008, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, 19, 399, 10.1007/s00198-008-0560-z

Odvina, 2005, Severely suppressed bone turnover: a potential complication of alendronate therapy, J Clin Endocrinol Metab, 90, 1294, 10.1210/jc.2004-0952

Abrahamsen, 2009, Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study, J Bone Miner Res, 24, 1095, 10.1359/jbmr.081247

Green, 1997, Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models, Pharmacol Toxicol, 80, 225, 10.1111/j.1600-0773.1997.tb01964.x

Perazella, 2008, Bisphosphonate nephrotoxicity, Kidney Int, 74, 1385, 10.1038/ki.2008.356

Genentech Inc.

Genentech Inc

Merck and Co. Inc

Novartis Pharmaceuticals Corporation

Warner Chilcott Pharmaceuticals Inc.

Jamal, 2007, Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial, J Bone Miner Res, 22, 503, 10.1359/jbmr.070112

Miller, 2005, Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials, J Bone Miner Res, 20, 2105, 10.1359/JBMR.050817

Miller, 2008, Renal safety across a wide range of dosing regimens of risedronate, J Bone Miner Res, 23, SA402

Jamal, 2010, The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function, Bone, 47, S207, 10.1016/j.bone.2010.04.491

Roelofs, 2010, Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo, J Bone Miner Res, 25, 606, 10.1359/jbmr.091009

Ferrari, 2010, Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture, Osteoporos Int, 21, S437, 10.1007/s00198-010-1250-1

Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, 1475, 10.1172/JCI119668

Recker, 2010, Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study, Bone, 46, 660, 10.1016/j.bone.2009.11.004

Ominsky, 2008, The effects of alendronate or denosumab on cortical and trabecular bone mass, bone strength, and bone mass–strength relationships in mice, J Bone Miner Res, 23, S40

Miller, 2009, Denosumab: anti-RANKL antibody, Curr Osteoporos Rep, 7, 18, 10.1007/s11914-009-0004-5

Masarachia, 1996, Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones, Bone, 19, 281, 10.1016/8756-3282(96)00182-2

McClung, 2006, Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies, Curr Osteoporos Rep, 4, 28, 10.1007/s11914-006-0012-7

Hiraga, 1996, Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor, Bone, 18, 1, 10.1016/8756-3282(95)00428-9